---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-002434"
form_type: "8-K"
ticker: null
cik: "0001260990"
company_name: "Oncternal Therapeutics, Inc."
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T02:57:35.129716+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oncternal pre-announces $34.3M cash; 20:1 reverse stock split effective Jan 8

## Summary
- Preliminary cash and cash equivalents of $34.3M as of Dec 31, 2023; subject to closing procedures.
- Shares outstanding: ~59.2M pre-split; ~3.0M post-split after 20:1 reverse stock split.
- Reverse stock split effective 12:01 a.m. ET on Jan 8, 2024; new CUSIP 68236P206.
- No fractional shares issued; fractional holders receive proportional cash payment.
- Exercise prices and share counts for stock options and warrants adjusted proportionally.

## SEC filing metadata
- accession: 0000950170-24-002434
- form_type: 8-K
- cik: 0001260990
- company_name: Oncternal Therapeutics, Inc.
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1260990/000095017024002434/0000950170-24-002434-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1260990/000095017024002434/onct-20240103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-002434
- JSON: https://secwatch.observer/filing/0000950170-24-002434.json
- Plain text: https://secwatch.observer/filing/0000950170-24-002434.txt

## Key facts
- Earnings Releases
  Oncternal Therapeutics, Inc. reported preliminary financial results for as of December 31, 2023.
  - Period: as of December 31, 2023
  - Result: preliminary results
  source text: Oncternal Therapeutics, Inc. (“Oncternal”) estimates that, as of December 31, 2023, its cash and cash equivalents were $34.3 million and it had 59.2 million shares of common stock, par value $0.001 per share (“Common Stock”) outstanding, or 3.0 million shares of Common Stock after giving effect to the Reverse Stock Split (defined below). These amounts are preliminary and are subject to completion of financial closing procedures.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1260990/000095017024002434/0000950170-24-002434-index.htm
- Governance Changes
  Oncternal Therapeutics, Inc.: Amended restated certificate of incorporation to effect a 1-for-20 reverse stock split (effective 2024-01-08).
  - Change: charter amendment
  - Effective: 2024-01-08
  source text: On January 3, 2024, Oncternal filed an amendment (the “Amendment”) to its restated certificate of incorporation to effectuate a reverse stock split of Oncternal’s Common Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1260990/000095017024002434/0000950170-24-002434-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.